Aurobindo Pharma has reported results for first quarter ended June 30, 2013.
The company has reported a net profit of Rs 143.63 crore for the quarter as compared to a net loss of Rs 49.84 crore for the same quarter in the previous year. Total income of the company has increased by 42.81% at Rs 1614.61 crore for quarter under review as compared to Rs 1130.61 crore for the quarter ended June 30, 2012.
On the consolidated basis, the group registered a net profit after taxes and minority interest at Rs 18.60 crore for the quarter as compared to a net loss of Rs 128.91 crore for the same quarter in the previous year. Total income of the company, on consolidated basis, has increased by 41.33% at Rs 1719.48 crore for quarter under review as compared to Rs 1216.63 crore for the quarter ended June 30, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: